Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays2009 · 2,209 citations
2. 2Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial2015 · 57 citations
3. 3A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma1997 · 34 citations
4. 4Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study2013 · 420 citations
5. 5International Staging System for Multiple Myeloma2005 · 2,941 citations